John R Moore has sold EWTX and made no open-market buys since May 2022

John R. Moore is the General Counsel of Edgewise Therapeutics, Inc. (EWTX), a clinical-stage biopharmaceutical company focused on small-molecule therapies for musculoskeletal diseases, and is a corporate insider who has reported transactions in Edgewise Therapeutics stock.( He has served as General Counsel of Edgewise since September 2020, bringing more than 15 years of senior legal leadership in the biopharmaceutical sector, including experience supporting drug research, clinical development, and corporate transactions.(

Before joining Edgewise, Moore was General Counsel and Secretary at Peloton Therapeutics, where he led the legal aspects of the company’s planned initial public offering and served as a key advisor on its acquisition by Merck.( Earlier, he spent 15 years as General Counsel and Secretary at Array BioPharma Inc. and served for five years on the board of directors of Nivalis Therapeutics, following earlier work as an attorney in private practice at Wilson Sonsini.( Moore holds a B.S. in chemistry and a J.D. from the University of North Carolina, as well as an M.S. in biochemistry from the University of Illinois, combining scientific training with legal expertise in supporting emerging biopharmaceutical companies.(

Written by Perplexity from public sources.